GlassScriptPhysician profile
Arumugam Sivakumar
NPI 1578563102
$7,252.20
in general payments reported to CMS, 2019-2025
22 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $618 · 2021: $881 · 2022: $1,313 · 2023: $1,134 · 2024: $1,706 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,577 · Education: $257 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.13 |
| Education | $256.99 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,559.93 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $1,479.20 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $567.98 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $529.80 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $336.76 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $263.04 | 2021-2023 | Suflave |
| Genzyme Corporation | $249.17 | 2022-2024 | |
| Pfizer INC. | $232.85 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $207.35 | 2020-2023 | |
| Ironwood Pharmaceuticals, INC | $141.50 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $130.30 | 2019-2024 | Rebyota |
| Gilead Sciences, INC. | $91.17 | 2019 | |
| Intra-Sana Laboratories | $86.10 | 2021-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Merck Sharp & Dohme LLC | $81.28 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $60.90 | 2022-2025 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $54.96 | 2019 | |
| Celgene Corporation | $47.76 | 2021-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $44.91 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $38.69 | 2025 | Rezdiffra |
| Alfasigma USA, INC. | $18.63 | 2020 | |
| Lucid Diagnostics INC. | $16.14 | 2023 | |
| Digestive Care, INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arumugam Sivakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.